India Pharma Outlook Team | Thursday, 09 October 2025
Nanomi B.V. (Nanomi) announced that a pharmaceutical company of global repute Lupin Limited (Lupin) has established a new strategic alliance programme which would make the long-acting injectable (LAI) platform PrecisionSphere more accessible.
The first product was approved by the U.S. Food and Drug Administration (FDA) recently, and the demonstrated effectiveness and safety of the platform for the delivery of the drug have allowed its commercial deployment.
The program, which is a vehicle for introducing partnerships, is designed to take into account pharmaceutical companies that, among other things, want to prolong the lifecycles of drugs by means of the development and also are oriented towards medicaments that can be improved by long-acting formulations.
President – Corporate Development, Lupin, Dr. Fabrice Egros, summarizing the Lupin advantage, said, “With PrecisionSphere validated and our successful annual track record of multiple strategic alliances, we are poised to expand patient access to advanced LAI treatments through global collaborations.” He spoke about the capability of the company in technology and expertise in the management of relations as a factor that adds to the strategic advantages of their partners seeking to introduce therapeutic LAI solutions at an accelerated rate.
Also Read: Lonza Secures Swissmedic Approval for Stein Facility
The Chief Scientific Officer of Lupin, Dr. Shahin Fesharaki, also concurred, “The adoption of PrecisionSphere as the way forward for LAI solutions is a testimony to our consistent efforts in applying regulatory knowledge, robust production process, and adaptable collaboration schemes to lower barriers for LAI development.” This not only facilitates the entry of advanced LAIs into the market in a time-efficient manner but also allows for the extension of product patent life, he added.
.jpg)
